Pyridomycin, a natural antibiotic exuded by the bacterium Streptomyces pyridomyceticus, shows promise as a candidate to fight a drug-resistant strain of TB, researchers in Switzerland said.
According to the UN's World Health Organisation (WHO) at least half a million of the eight to nine million people who each year develop TB have a strain that is resistant to frontline drugs.
Pyridomcycin works by inhibiting a single gene called InHA which, in mutant strains, helps the TB microbe thwart isoniazid drugs.
